Development of a drug delivery system using a model that mimics chronic infection of Mycobacterium bovis Calmette-Guerin in alveolar macrophages.
Macrophages play a dominant role in defense against infective organisms and their regarded abilities can be positioned as their most primitive and important function. On the other hand, tuberculosis, caused by tubercle bacilli which possess the ability to survive in phagosome and grow in cell, poses a serious problem as an intractable disease because the efficacy of drug delivery to the target bacilli is low. We have developed a new approach to therapy against intracellular bacteria using a drug delivery system (DDS), to deliver an effective amount of drug to the target site, based on the phagocytotic ability of macrophages. In this review, the development of an in vitro model of chronic infection by tubercle bacilli and therapy against tuberculosis using phagocytosis by macrophages and a DDS with microspheres are described.
Yoshida
Aya
A
Faculty of Engineering, The University of Tokushima, Minamijyousanjima-cho, Tokushima-shi, Tokushima, Japan.
Inagawa
Hiroyuki
H
Kohchi
Chie
C
Nishizawa
Takashi
T
Hori
Hitoshi
H
Soma
Gen-Ichiro
G
D000818:Animals; D002478:Cells, Cultured; D016503:Drug Delivery Systems; D006016:Glycolates; D019344:Lactic Acid; D016676:Macrophages, Alveolar / Q000382:microbiology*; D008863:Microspheres; D008954:Models, Biological; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D010587:Phagocytosis; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D051381:Rats; D012293:Rifampin / Q000627:therapeutic use*; D014376:Tuberculosis / Q000188:drug therapy*
D006016:Glycolates; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D012293:Rifampin